Based in New York, USA, AiCure was founded by Adam Hanina and Laura Shafner in 2010. AiCure is a data-analytics company that uses artificial intelligence to understand how patients respond and comply with medication treatments. The AI assists with patient/ provider decision-making and records patient outcomes. Additionally, AiCure developed a patented facial recognition and motion-sensing application; accessible by a front-facing smartphone camera, that tracks real-time medication compliance and ingestion. AiCure is funded by the National Institutes of Health (NIH) as well as investors. AiCure has over 65 patents and has expanded globally to over 30 countries.
AiCure uses artificial intelligence to see, hear, and understand how patients respond to treatment. Additionally, AiCure developed the aforementioned IMA, an interactive medical assistant, available via a smartphone with camera, to assist patients and ensure they receive treatment or follow medication compliance routine.
COVID-19 Response and Contribution:
COVID-19 is changing the way the industry thinks about preserving clinical trials while ensuring patient safety. AiCure enables continuity by providing remote and direct patient communication and engagement, ensuring assessments, medication adherence, virtual registration, training, and payments. Sites can continue to provide care and stay closely connected to their patients with a trusted provider of direct site and patient communication for a decade. AiCure is working with sites to maintain their patient relationship via video chat (telehealth) in a HIPAA and GDPR compliant manner while maintaining patient safety and privacy.
AiCure Launches Platform to Remotely Capture Digital Biomarkers in Clinical Trials
AiCure has a post-money valuation in the range of $100M to $500M as of Nov 8, 2019 according to PrivCo.
Their latest funding was raised on Nov 7, 2019 from a Series C round. AiCure is funded by 11 investors. Singtel Innov8 and New Leaf Venture Partners are the most recent investors.
Aicure raises a $24,500,000 series C round from Asahi Kasei, New Leaf Venture Partners, SingTel Innov8, Biomatics Capital Partners, Silicon Valley Bank, Accelmed Growth Partners, Tribeca Venture Partners, Palisades Growth Capital, Springrock Ventures, Baird Capital and Pritzker Group Venture Capital.
Aicure raises a $15,000,000 series B round from New Leaf Venture Partners, Biomatics Capital Partners, Tribeca Venture Partners, Pritzker Group and Baird Capital.
Aicure raises a $12,300,000 series A round from Biomatics Capital Partners, New Leaf Venture Partners, Pritzker Group and Tribeca Venture Partners.
AI-Enabled Drug Discovery & Clinical Trials Market 2020-2026 Increasing Drug Development Expenditure By Major Key Players: AiCure, LLC, Berkeley Lights, Inc., CytoReason, Exscientia Limited, Mind the Byte, Symphony Innovation, LLC - 3w Market News Reports
June 22, 2020
AiCure | NIH SBIR/STTR
AiCure's strategy of providing data for life sciences reinforced by record economic momentum
January 14, 2020
New Research Sheds Light on Intentional Non-adherence in Clinical Trials
June 15, 2020